Literature DB >> 11578020

Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus.

E Balada1, J Ordi-Ros, F Paredes, J Villarreal, M Mauri, M Vilardell-Tarrés.   

Abstract

OBJECTIVE: To evaluate the correlation between antiphosphatidylethanolamine antibodies (aPE) and some antiphospholipid antibodies (aPL)-related clinical manifestations in patients with systemic lupus erythematosus (SLE).
METHODS: Patients with SLE (n=217) were tested for the presence of aPE, anticardiolipin antibodies (aCL), and lupus anticoagulant (LA). The prospective aPL-related clinical manifestations studied were: thrombosis, thrombocytopenia, recurrent fetal losses, heart valvulopathies, hemolytic anemia, livedo reticularis, and pulmonary hypertension.
RESULTS: A total of 109 SLE patients (50.23%) were IgG aPE-positive; 17.51% presented aPE as the sole autoantibody and had some clinical features of aPL-related clinical manifestations. IgG aPE were associated to the presence of heart valvulopathies (p=0.002). A statistical difference was also found when considering high levels of IgG aPE (O.D.>0.600) in patients with livedo reticularis (p=0.008).
CONCLUSION: The evaluation of IgG aPE may allow us to detect some more patients with aPL-related clinical manifestations in the SLE population, aPE correlated particularly with valvulopathies and livedo reticularis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578020     DOI: 10.1080/030097401316909594

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.

Authors:  Songwang Hou; Heike Fölsch; Ke Ke; Joan Cook Mills; Rosalind Ramsey-Goldman; Ming Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

3.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

Review 4.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

5.  Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and thrombotic autoimmunity.

Authors:  Clive W Wells; Paula E North; Suresh Kumar; Christine B Duris; John A McIntyre
Journal:  Clin Appl Thromb Hemost       Date:  2009-11-10       Impact factor: 2.389

Review 6.  Livedo reticularis as a criterion for antiphospholipid syndrome.

Authors:  E Toubi; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.